Short answer
What is BPC-157? BPC-157 is a synthetic 15-amino-acid peptide (sequence GEPPPGKPADDAGLV) first identified from human gastric juice. Researchers study it in tissue remodeling, angiogenesis and gastrointestinal research models. It is sold as a lyophilized research powder and is not for human use.
What does BPC-157 stand for?
BPC stands for body protection compound, and 157 identifies the specific peptide described in the research literature. The peptide was first reported in the early 1990s after being isolated from human gastric juice. A 2026 review in the International Journal of Molecular Sciences summarizes decades of laboratory work on BPC-157 in tissue repair and related research models [1], and a foundational 2011 review in Current Pharmaceutical Design by Sikiric and colleagues catalogued its reported effects across the gastrointestinal tract and beyond [2].
Sequence and molecular properties
BPC-157 is a pentadecapeptide, meaning it is built from exactly 15 amino acids. Its sequence is GEPPPGKPADDAGLV: glycine, glutamic acid, three proline residues, glycine, lysine, proline, alanine, two aspartic acid residues, alanine, glycine, leucine and valine. The theoretical molecular weight is approximately 1419 Da, which gives researchers a simple mass-spectrometry check: if the observed mass matches the expected value, the material is almost certainly the intended sequence [2].
Because the molecule is short and its chemistry is well characterized, it can be produced with standard solid-phase peptide synthesis. The practical implication is that identity verification is straightforward and a competent manufacturer can reproducibly deliver high-purity material. What varies between suppliers is the rigor of purification and the quality of documentation, which is why the buying checklist later in this article is worth reading carefully.
What makes BPC-157 stable?
One of the earliest observations about BPC-157 was its reported stability in conditions that would degrade most peptides. It was originally studied because a compound found in gastric juice appeared to tolerate the harsh, acidic, enzyme-rich environment of the stomach, and later work reported stability in saline as well [2]. This is unusual. Most unmodified peptides are cleaved quickly by proteases in biological fluids, which is why peptide researchers so often rely on modified sequences, protective carriers or continuous delivery systems.
That stability profile is one reason BPC-157 continues to appear in research designs where a peptide needs to remain intact long enough to produce a measurable effect. It also means the material can be handled with fairly standard laboratory workflows, though good storage discipline still matters (see the storage section below).
How is BPC-157 studied in the laboratory?
Scientists study BPC-157 at the cell and animal level. The most common research themes include:
Across these studies, BPC-157 is usually described as a peptide that has been investigated for its effects in research models, not as a drug with proven human benefits [1].
In practice, cell-based work typically uses cultured fibroblasts, endothelial cells or gastrointestinal cell lines, while animal work commonly relies on rodent models of induced tissue damage. Concentration-response experiments are a standard design: cells are exposed to a range of concentrations and migration, survival or matrix output is measured to establish whether the observed effect is concentration-dependent, as in the tendon study cited earlier [3]. Because the peptide is short and unmodified, it is usually delivered as a simple solution rather than requiring specialized carriers, which keeps the experimental setup straightforward.
Signaling mechanisms under investigation
Several mechanistic threads run through the BPC-157 literature, and most center on processes that cells need in order to repair tissue: migration, survival, proliferation and blood supply.
In tendon research, a 2011 study in the Journal of Applied Physiology showed that BPC-157 accelerated the outgrowth of tendon explants, improved cell survival under oxidative stress and increased fibroblast migration in a concentration-dependent manner, with the authors linking the effects to the FAK-paxillin signaling axis [3]. Focal adhesion kinase (FAK) and paxillin are proteins that cells use to sense their surroundings and move across surfaces, so this pathway is a concrete molecular readout for the migration effects reported in other models.
Angiogenesis is the other recurring theme. New blood vessel formation requires endothelial cells to proliferate, migrate and assemble into tubular networks, and BPC-157 has been studied in settings where vessel growth is rate-limiting, such as hypovascular tendon and ligament tissue. A 2019 review in Cell and Tissue Research critically evaluates the musculoskeletal literature and notes that BPC-157's reported effects include promoting angiogenesis in poorly vascularized soft tissues, while also flagging that most of the evidence comes from rodent models [4].
The nitric oxide (NO) pathway also appears across BPC-157 research. NO influences blood flow, endothelial function and many repair processes, and gastrointestinal and vascular studies have reported interactions between BPC-157 and NO-related signaling [2]. Researchers who design follow-up experiments often include assays for these specific mediators - migration markers, vascular markers and NO-related readouts - rather than assuming the peptide acts through a single, well-defined mechanism.
Experimental considerations for BPC-157 research
A few practical points recur when labs design BPC-157 studies. First, choose the end-point before choosing the model. If the hypothesis is about blood vessel formation, an endothelial tube-formation assay or a vascular stain in an animal model is a direct readout; if the hypothesis is about matrix remodeling, collagen assays or matrix metalloproteinase measurements fit better. Second, include the appropriate vehicle controls, because peptide solutions are made up in buffers that can themselves influence cell behavior. Third, pay attention to the salt form: many peptides are supplied as trifluoroacetate (TFA) salts, and at high concentrations the TFA counter-ion can affect cell viability, so the COA should state the salt form.
Finally, remember that reported effects are typically concentration-dependent. Running a concentration series and reporting the range tested makes an experiment more informative and easier to compare with the published literature.
Reading the BPC-157 literature critically
It is worth being honest about the state of the evidence. The vast majority of BPC-157 studies are cell-based or use animal models, and the 2026 International Journal of Molecular Sciences review itself notes that human data remain limited [1]. The peptide has no regulatory approval for any use, it is not a recognized drug, and it appears on some sporting organizations' prohibited lists. None of this means the research is without interest - it simply means the material belongs in the laboratory, studied for its mechanisms in research models, not promoted for effects beyond what the evidence supports.
A critical reader also notices that the literature spans several decades and uses many different model systems, which makes direct comparisons between studies difficult. Standardizing the peptide source, confirming identity and purity by mass spectrometry and HPLC, and reporting concentrations transparently all help a lab generate results that are meaningful within its own protocol and comparable to the published work.
BPC-157 in context: how it compares to related peptides
Because BPC-157 is studied heavily in repair-focused research, it is often discussed alongside other peptides in the same broad space. TB-500 (a thymosin beta-4 fragment) is studied for actin-binding and cell migration, a mechanism anchored in the cytoskeleton rather than in tissue-specific repair signaling. The two are sometimes combined in pre-measured research blends because they address different pathways, but each has its own independent literature base. GHK-Cu, a copper-binding tripeptide, is studied more heavily in dermal and extracellular matrix remodeling models.
For a side-by-side look at the two most commonly compared repair peptides, see our BPC-157 vs TB-500 comparison.
Storage and handling
Lyophilized (freeze-dried) BPC-157 is the standard research form because removing water dramatically slows the chemical degradation that occurs in solution. Key handling points:
For a deeper walkthrough, see our peptide storage guide.
What to check before buying BPC-157
Research-grade BPC-157 should always come with verifiable quality data. Before ordering, confirm:
You can review PEPMAKE's batch verification portal and browse BPC-157 research product options for an example of what batch documentation looks like.
FAQ
What is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide modeled on a compound first isolated from human gastric juice. It is used in laboratory research only.
What does BPC stand for?
BPC stands for body protection compound; 157 identifies the specific peptide variant described in the literature.
Is BPC-157 for human use?
No. PEPMAKE sells BPC-157 as a lyophilized powder for in-vitro laboratory research only.
What purity should research-grade BPC-157 have?
At least 99% by HPLC, with identity confirmed by mass spectrometry and a batch-specific COA.